According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is ₹14.86 Billion. In 2023 the company made a revenue of ₹5.01 Billion an increase over the revenue in the year 2022 that were of ₹2.24 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.